Page last updated: 2024-09-04

cinacalcet and Vomiting

cinacalcet has been researched along with Vomiting in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GFM; Tonelli, M1
Akizawa, T; Fukagawa, M; Haruyama, W; Hisada, Y; Kawata, T; Masuda, N; Miyazaki, H; Murai, M; Shoukei, Y; Tokunaga, S; Wada, M; Yanagida, T1
Ariceta, G; Dehmel, B; Hidalgo, G; Iles, JN; Jiang, X; Laskin, B; Schaefer, F; Shahinfar, S; Vande Walle, J; Warady, BA1
Covic, A; Craig, JC; Messa, P; Nistor, I; Palmer, SC; Pellegrini, F; Strippoli, GF; Tonelli, M1
Block, GA; Bushinsky, DA; Cheng, S; Chertow, GM; Cunningham, J; Dehmel, B; Drueke, TB; Ketteler, M; Kewalramani, R; Martin, KJ; Moe, SM; Patel, UD; Silver, J; Sun, Y; Wang, H1
Emery, M; Padhi, D; Salfi, M1
Lopez, J; Norman, J; Politz, D1

Reviews

2 review(s) available for cinacalcet and Vomiting

ArticleYear
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:3

    Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cinacalcet; Comorbidity; Female; Fractures, Bone; Heart Failure; Humans; Hyperparathyroidism, Secondary; Male; Mortality; Naphthalenes; Nausea; Parathyroid Hormone; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vomiting

2020
Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
    PLoS medicine, 2013, Volume: 10, Issue:4

    Topics: Calcimimetic Agents; Calcium Metabolism Disorders; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Nausea; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vomiting

2013

Trials

3 trial(s) available for cinacalcet and Vomiting

ArticleYear
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Pediatric nephrology (Berlin, Germany), 2019, Volume: 34, Issue:3

    Topics: Adolescent; Calcimimetic Agents; Calcium; Child; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypertension; Hypocalcemia; Male; Nausea; Parathyroid Hormone; Placebos; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D; Vomiting

2019
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    JAMA, 2017, 01-10, Volume: 317, Issue:2

    Topics: Administration, Oral; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Nausea; Parathyroid Hormone; Peptides; Renal Dialysis; Time Factors; Vomiting

2017
Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Drugs in R&D, 2008, Volume: 9, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Calcium; Calcium Channel Agonists; Cinacalcet; Cross-Over Studies; Cytochrome P-450 CYP3A; Data Interpretation, Statistical; Female; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Male; Midazolam; Middle Aged; Naphthalenes; Nausea; Paresthesia; Vomiting; Young Adult

2008

Other Studies

3 other study(ies) available for cinacalcet and Vomiting

ArticleYear
A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Administration, Oral; Animals; Calcimimetic Agents; Callithrix; Cinacalcet; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gastrointestinal Tract; HEK293 Cells; Humans; Isoenzymes; Male; Molecular Structure; Parathyroid Glands; Parathyroid Hormone; Rats, Wistar; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Vomiting

2018
Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Bone Density; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Primary; Male; Middle Aged; Naphthalenes; Nausea; Osteoporosis; Treatment Failure; Vomiting; Young Adult

2012
Cinacalcet (sensipar).
    The Medical letter on drugs and therapeutics, 2004, Sep-27, Volume: 46, Issue:1192

    Topics: Cinacalcet; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Hypocalcemia; Naphthalenes; Nausea; Vomiting

2004